BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/22/2022 9:25:37 AM | Browse: 658 | Download: 2247
 |
Received |
|
2021-10-21 14:53 |
|
Peer-Review Started |
|
2021-10-21 14:55 |
|
First Decision by Editorial Office Director |
|
2021-12-02 08:56 |
|
Return for Revision |
|
2021-12-02 08:56 |
|
Revised |
|
2021-12-15 14:01 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-02-15 03:19 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-02-16 07:18 |
|
Articles in Press |
|
2022-02-16 07:18 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-02-17 07:03 |
|
Publish the Manuscript Online |
|
2022-02-22 09:25 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mitchell L Ramsey, Michael R Wellner, Kyle Porter, Stephen E Kirkby, Susan S Li, Luis F Lara, Sean G Kelly, A James Hanje and Lindsay A Sobotka |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Lindsay A Sobotka, Consultant, Assistant Professor, Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, 410 West 10th Avenue, Columbus, OH 43210, United States. lindsay.sobotka@osumc.edu |
| Key Words |
Cirrhosis; Ursodiol; Transmembrane; Cystic fibrosis; Market scan; Cystic fibrosis related liver disease |
| Core Tip |
The effect of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on hepatobiliary outcomes in cystic fibrosis (CF) patients remains unknown. Utilizing a nationwide database, the incidence of cirrhosis in CF patients utilizing CFTR modulators, ursodiol, combination therapy or neither therapy was compared. A total of 7201 patients were studied including 12.6% on a CFTR modulator, 7.0% on ursodiol, 6.1% on combination therapy and 74.3% on neither therapy. Patients taking CFTR modulators had a lower incidence of cirrhosis than untreated patients (P = 0.05), or patients treated with Ursodiol (P < 0.001) or Ursodiol and CFTR modulators (P = 0.003). CFTR modulators may reduce the incidence of cirrhosis in patients with CF. |
| Publish Date |
2022-02-22 09:25 |
| Citation |
Ramsey ML, Wellner MR, Porter K, Kirkby SE, Li SS, Lara LF, Kelly SG, Hanje AJ, Sobotka LA. Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis. World J Hepatol 2022; 14(2): 411-419 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i2/411.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i2.411 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
